Parkinson's disease treatments: focus on transcranial direct current stimulation (tDCS) by Tahtis, V & Kaski, D
© 2017 Tahtis and Kaski. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Journal of Parkinsonism and Restless Legs Syndrome 2017:7 55–70
Journal of Parkinsonism and Restless Legs Syndrome Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
55
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JPRLS.S128146
Parkinson’s disease treatments: focus on 
transcranial direct current stimulation (tDCS)
Vassilios Tahtis1
Diego Kaski1,2
1Division of Brain Sciences, Imperial 
College London, Charing Cross 
Hospital Campus, 2Sobell Department 
for Motor Control and Movement 
Disorders, University College London, 
London, UK 
Abstract: Parkinson’s disease (PD) is among the most common progressive neurodegenerative 
conditions worldwide, characterized by bradykinesia, rigidity, tremor, and postural instability, in 
addition to a variety of cognitive and behavior complications. Current pharmacological treatment 
options focus on dopaminergic replacement, but these become less efficacious as the disease 
progresses. Noninvasive brain stimulation techniques have therefore gained favor in recent 
years as a means of treating the motor and non-motor complications of PD. Here we review the 
evidence behind the use of transcranial direct current stimulation in the treatment of motor and 
non-motor complications of PD, discuss the limitations that have hindered the introduction of 
transcranial direct current stimulation into mainstream clinical practice, and highlight future 
directions that may enable the translation of this research tool into clinical use.
Keywords: Parkinson’s disease, transcranial direct current stimulation, motor, cognitive, 
non-motor
Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by 
resting tremor, rigidity, bradykinesia, and postural instability, in addition to non-motor 
complications that may predate the motor symptoms. As one of the most common 
human degenerative disorders, it has a major socio-economic impact worldwide. The 
motor complications result from loss of dopaminergic neurons in the substantia nigra 
of the basal ganglia, and thus pharmacological treatments focus on dopamine replace-
ment, most commonly with levodopa, or dopamine agonists. It is a well-recognized 
phenomenon that treatment response diminishes as the disease progresses, alongside 
the development of additional symptoms from degeneration of non-dopaminergic 
neuronal systems. One feature of such progression is the emergence of gait and pos-
tural disturbance that is often refractory to treatment and becomes a central cause of 
disability. So-called non-motor complications of PD include constipation, anosmia, 
sexual dysfunction, and sleep abnormality. 
Cognitive and behavioral deficits and psychiatric manifestations are a further 
hallmark of this disorder which become evident as the disease progresses and increase 
with the age and severity of the disease.1 These symptoms are often overlooked but 
may have a devastating impact on the function and quality of life of patients with PD,2 
being notoriously difficult to treat. 
It is increasingly recognized that there may be an optimal time window to consider 
surgical interventions – primarily deep brain stimulation (DBS) targeting a variety 
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of nuclei – for motor complications of PD; during the early 
stages of the disease, patients typically respond well to oral 
medications, whereas with very advanced disease axial motor 
signs and psychiatric complications, they may respond less 
well to DBS. Thus, DBS is of particular benefit between the 
occurrence of levodopa-induced motor complications and the 
development of levodopa-resistant symptoms. DBS requires 
careful patient selection in light of the potential neurosurgical 
and anesthetic risks and in some patients can have significant 
neuropsychiatric sequelae. Consequently, there has been a 
growing need to supplement pharmacological treatments 
for PD with less invasive stimulation techniques that do not 
impose surgical risks. Therapeutic studies of non-invasive 
brain stimulation, including repetitive transcranial magnetic 
stimulation (rTMS), have yielded promising results in PD. 
Two meta-analyses concluded that there was a modest thera-
peutic effect of rTMS in motor performance in PD,3,4 with 
no safety concerns.
Transcranial direct current stimulation (tDCS) is a mode 
of non-invasive brain stimulation whereby a direct current is 
delivered to the head via surface electrodes positioned on the 
scalp to induce polarity-dependent changes of the underlying 
cortex. The use of this technique to modulate cortical excit-
ability5 and promote motor and cognitive learning in healthy 
adults6 and motor recovery in chronic stroke7 has raised inter-
est in tDCS as an intervention in PD. While tDCS has been 
shown to improve motor learning and cognitive function in 
PD, outcomes have been mixed. 
Here we review the evidence behind the use of tDCS in 
the treatment of motor and non-motor complications of PD, 
discuss the limitations that have hindered the introduction of 
tDCS into mainstream clinical practice, and highlight future 
directions that may enable the translation of this research 
tool into clinical use.
Search strategy
The search focused on published literature with search aggre-
gators used to access content from key databases. OvidSp, 
PubMed, EBSCO Host, and Google Scholar were all used. 
Terms were searched in systematic, alternate combinations to 
optimize the depth of the search and included (with variations): 
Parkinson’s, bradykinesia, dyskinesia, tDCS, transcranial, direct 
current, NIBS, non-invasive, brain stimulation, anodal, cath-
odal. The two authors independently read titles and abstracts 
to exclude papers irrelevant to the review. The focus of the 
search was on experimental clinical research which investi-
gated the efficacy of tDCS in PD and any associated symptoms 
(motor and non-motor). Papers that met this inclusion criteria 
(experimental research, participants, and intervention) were 
retrieved in full and again checked for applicability by the 
two authors. Publications in English were only included, and 
we also searched the reference lists of any studies identified. 
This search process was repeated at regular intervals until June 
2017. No date restriction was applied to the search. Similar to 
Lefaucheur’s comprehensive review,8 we chose to exclude three 
studies that used tDCS as a priming mechanism for testing an 
alternative intervention, namely rTMS.9–11 
tDCS
tDCS involves the delivery of a low-intensity current (1–2 
mA) using relatively large electrodes (~2–10 cm) gener-
ally placed on the scalp. Most studies of tDCS employ a 
“ bipolar” montage consisting of one anode and one cathode 
to induce an electric field that passes across the various cra-
nial structures (skin, bone, pia, and cerebrospinal fluid) to 
reach the brain parenchyma. The size of the electric field over 
the brain parenchyma varies across studies from 0.3 to1.6 
V/m – according to head models or in vivo measurements – 
reflecting anatomical differences between individuals, 
electrode size, shape, and placement.12–14 Computational 
modeling has offered insights into the mechanism of action 
of tDCS, although much work is still needed to better define 
the current flow across and between cerebral structures. For 
example, controversy abounds regarding whether the peak 
current densities beneath the electrodes are sufficient to 
modulate neuronal activity. However, experimental data do 
suggest that neurons are sensitive to such weak electric fields, 
resulting in modulation of action potential firing, synaptic 
plasticity, and promotion of neurogenesis,15–17 in addition to 
subtle effects on supporting glial cells.18,19 One of the experi-
mental benefits of tDCS is the ability to administer a “sham” 
stimulation that naïve subjects cannot differentiate from 
“real” stimulation, allowing for the design of controlled stud-
ies. This form of placebo is usually achieved by delivering a 
brief (<30  seconds) ramp current causing a mild subjective 
sensation over the scalp and then turning the stimulation off. 
Recently published studies on animal models provide 
strong evidence for the potential of tDCS to modulate dopami-
nergic pathways. Frontal tDCS in rats20 and tDCS in a mouse 
model of PD21 led to increased dopaminergic release, resulting 
in an elevation of striatal dopamine levels, in some instances 
lasting for more than 6 hours after stimulation. In a monkey 
model of advanced PD, frontal anodal tDCS was shown to 
activate neurons in the dopaminergic substantia nigra.22
It should be noted that tDCS differs from other methods of 
cortical stimulation, such as rTMS, which are able to induce 
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sufficient current intensity to directly elicit action potentials 
from cortical axons.23,24 Conversely, tDCS has been shown to 
modulate the resting membrane potential of cortical axons in 
the direction of depolarization or hyperpolarization, according 
to the polarity of the electrodes (anode vs cathode) and the 
orientation of the axons in the induced electric field. In its most 
simplistic form, anodal tDCS induces neuronal depolarization 
(excitability) and cathodal tDCS hyperpolarization (inhibition). 
Early into the phase of renewed interest in tDCS, experiments 
demonstrated excitability changes which persisted beyond the 
stimulation period.5 This post-stimulation modulation of neu-
ronal excitability over long periods (up to 90 minutes) renders 
tDCS an attractive therapeutic tool in patients with PD. 
Table 1 summarizes the current studies exploring the use 
of tDCS in patients with PD, across motor and non-motor 
domains. Discussion of these studies according to the motor 
or cognitive target is as follows.
tDCS for upper limb motor function  
in PD
Bradykinesia is considered to be the defining feature of PD, 
clinically evident as a decrement in the amplitude and velocity 
of repetitive movements.2 In one of the first studies of tDCS in 
PD, Fregni et al25 evaluated the effects of tDCS on both motor 
function – as assessed by Unified Parkinson’s Disease Rating 
Scale (UPDRS) part III, simple reaction time, and Purdue 
Pegboard test (a test of manual dexterity) – and motor-evoked 
potentials (MEPs) of the hand in patients with PD. They 
applied anodal tDCS over the primary motor cortex (M1; n=9), 
cathodal stimulation of M1 (n=8), and anodal stimulation of 
dorsolateral prefrontal cortex (DLPFC, a cortical area involved 
primarily in cognitive processes – see tDCS for cognition 
section; n=9). All stimulations were compared to sham, in a 
double-blinded manner. A constant current of 1 mA intensity 
was applied for 20 minutes. They found that anodal stimulation 
of M1 was associated with a significant improvement of motor 
function compared to sham stimulation in the UPDRS part 
III (21.9% mean improvement after active tDCS compared to 
−1.6% with sham stimulation) and reaction times. Although 
the study was not powered to assess multiple comparisons, 
descriptive analysis suggested that improvements in UPDRS 
seemed to be driven mostly by changes in rigidity and to a less 
degree bradykinesia. This effect was not observed for cathodal 
stimulation of M1 or anodal stimulation of DLPFC, although a 
small ( nonstatistically significant) improvement in motor func-
tion was noted. Furthermore, whereas anodal stimulation of 
M1 significantly increased MEP amplitude, cathodal stimula-
tion of M1 significantly decreased the amplitude. Thus, tDCS 
over M1 was able to modulate neuronal excitability – manifest 
as increased hand MEPs – and such neuronal changes may 
underpin the improvement in motor function in patients with 
PD. The number of participants in each experiment presenting 
with their left or right side most-affected was almost equal; 
however, the authors did not consider lateralization effects (see 
Key considerations for a large-scale, multicenter clinical trial 
of tDCS in PD section). 
Benninger et al26 investigated the efficacy of tDCS in 
the treatment of motor and cognitive aspects of PD using 
a randomized, double-blind, sham-controlled study design. 
Anodal tDCS (2 mA) was delivered for 20 minutes through 
a large electrode (surface 97.5 cm2; current density 0.021 
mA/cm2) that was placed symmetrically over either the 
premotor and motor (electrode center 10 mm anterior to 
Cz) or the prefrontal cortices (forehead above eyebrows 
147 mm anterior to Cz). They stimulated a single target 
area during one session and alternated the position of the 
anode between sessions (starting with the motor area) so 
that each target area was stimulated four times. A cathode 
electrode (25 cm2 each) was positioned over each mastoid. 
Patients underwent eight treatment sessions over a period 
of 2.5 weeks, with a minimum washout period of 48 hours. 
Bradykinesia significantly improved with tDCS compared to 
sham intervention (−28.4% vs −11%, p=0.002, when “on” 
and −36.0% vs −17.8%, p<0.0001, when “off ”). Although 
bradykinesia improved irrespective of whether patients were 
“on” or “off ” dopaminergic medication, the rate of change 
was greater during “off ” periods. A link between tDCS and 
dopamine has been investigated experimentally, with a sug-
gestion that l-dopa can reduce the tDCS-related modulation 
of cortical excitability,27 in keeping with the observations in 
this study. However, this study employed a different tDCS 
montage for the sham stimulation compared to the active 
stimulation, raising concerns about the methodological rigor.
Doruk et al28 performed a sham-controlled, double-
blinded study across two centers, assessing the immediate and 
long-term effects of ten consecutive sessions of tDCS over the 
anode on the right DLPFC (n=5), left DLPFC (n=6) or sham 
(n=7). Although the primary outcomes were cognition and 
mood, they evaluated the motor function. As expected, given 
the findings of Fregni et al25 and neuroanatomical evidence 
supporting a more cognitive function of DLPFC, they did not 
find any significant improvements on the UPDRS part III, 
Purdue Pegboard, or reaction times with tDCS. 
Costa-Ribero et al showed no difference between primary 
motor cortex anodal tDCS and sham (when combined with 
gait training) in bradykinesia subscores of the UPDRS.29 
Similarly, Schabrun et al30 combined anodal (and sham) 
stimulation with repeated gait training sessions and recorded 
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Table 1 Summary of studies exploring the use of tDCS across motor and non-motor complications in Parkinson’s disease
Authors Year Motor Cognitive Other Electrode 
size (cm2)
Electrode 
intensity 
(mA)
Anode Cathode Sessions Duration 
per session 
(minutes)
Study type Adjunct Disease 
state 
(HY)
Sample Active Sham Outcomes Result
Boggio 
et al71
2006 Working 
memory
35 1 Left DLPFC; M1 
(left assumed)
Contralateral 
right orbit
2 20 Single-blind 
(assumed); cross-
over
9 9 9 Three-back letter working 
mem paradigm
Nonsignificant
2 Left DLPFC; M1 
(left assumed)
Contralateral 
right orbit
2 20 Single-blind 
(assumed); cross-
over
9 9 9 Three-back letter working 
mem paradigm
Significant (DLPFC 
only)
Fregni et al25 2006 UL 35 1 Left M1 Right 
supraorbital
1 20 Double-blind; 
cross-over
2.4 HY 9 9 9 MEP; UPDRS; sRT; PPT Significant
35 1 Right supraorbital Left M1 1 20 Double-blind; 
cross-over
8 8 8 MEP; UPDRS; sRT; PPT Nonsignificant
35 1 Left DLPFC Right 
supraorbital
1 20 Double-blind; 
cross-over
9 9 9 UPDRS; sRT; PPT Significant
Benninger 
et al26
2010 Gait and 
UL
Reaction 
time
Depression 97.5 (anode); 
25 (cathode)
2 10 cm anterior to 
Cz × 4 sessions; 
prefrontal 
cortices 
(forehead above 
eyebrows) × 4 
sessions
Mastoids 8 (2/3 pw) 20 Double-blind 2.4±0.2 25 13 12 10 m walk; UL 
bradykinesia; UPDRS; sRT; 
BDI; health survey; SelfAx 
of mobility
Nonsignificant
Pereira 
et al76
2013 Verbal 
fluency
35 2 Left DLPFC or 
left TPC
Right 
supraorbital
1 (left 
DLPFC) + 1 
(left TPC)
20 Crossover; 
no blinding (2 
montages tested)
1.6±0.5 
HY
16 32 0 Verbal fluency (fixation, 
repetition, semantic, 
phonemic); fMRI
Significant (DLPFC 
over TPC)
Verheyden 
et al41
2013 Gait and 
posture
Not stated 1 M1 of dominant 
hemisphere
Contralateral 
supraorbital
1 + sham 15 Double-blind; 
cross-over
1–4 HY 20 20 20 Sit to stand; functional 
reach; 180o turn; TUG; 
10 m walk
Nonsignificant
Doruk et al28 2014 UL Exec Mood/
behavior
35 2 Left or right 
DLPFC
Supraorbital 
contralateral 
to anode 
placement
10 (5 pw) 20 Double-blind; 
2 site
18 11 (6+5) 7 TMT A&B; WCST; PCL; 
WM; Stroop; HPVOT; 
CPM; MMSE; BDI; HAS; 
UPDRS III; sRT; 4-CRT; 
PPT; FT; WT; BU; SP
Significant (cog not 
motor)
Kaski et al50 2014 Gait Anode: 40; 
cathode: 40
2 Anterior to Cz Inion 1 15 Double-blind; 
RCT; cross-over
Physical 
therapy during 
stimulation
16 8 8 Gait velocity; TUG Significant
Manenti 
et al54
2014 Gait 35 2 Left then right 
DLPFC for all 
patients
Contralateral 
supraorbital
2 7 Double-blind; 2 
montages tested 
on each patient 
L&R DLPFC
1.3±1.1 10 20 10 TUG Significant (right 
DLPFC)
Valentino 
et al56
2014 Gait Not stated 2 M1 corresponding 
to leg, patient 
started walking 
post freezing
Contralateral 
orbitofrontal
5 20 Double-blind; 
cross-over
2–4 HY 10 10 10 Motor UPDRS; stand-
walk-sit
Significant
Biundo 
et al53
2015 MCI 2 Left DLPFC Right 
supraorbital 
16 (4 pw) 20 Double-blind Computer-
based cog 
training
24 12 12 RBANS Significant
Salimpour 
et al31
2015 UL N/A N/A Experiment 1: No 
stimulation
No 
stimulation
N/A N/A N/A 1–2.5 HY 15 PD + 
15 Healthy
N/A N/A N/A N/A
25 1 Experiment 2: 
Left M1
Right M1 1 25 Not stated 10 10 0 UPDRS (motor assumed); 
bimanual UL task; 
unimanual task; unimanual 
max force
Nonsignificant
25 (assumed) 2 Experiment 3: 
Right M1
Left M1 1 25 Not stated 10 10 0 Motor UPDRS; bimanual 
UL task; unimanual task; 
unimanual max force
Significant
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Table 1 Summary of studies exploring the use of tDCS across motor and non-motor complications in Parkinson’s disease
Authors Year Motor Cognitive Other Electrode 
size (cm2)
Electrode 
intensity 
(mA)
Anode Cathode Sessions Duration 
per session 
(minutes)
Study type Adjunct Disease 
state 
(HY)
Sample Active Sham Outcomes Result
Boggio 
et al71
2006 Working 
memory
35 1 Left DLPFC; M1 
(left assumed)
Contralateral 
right orbit
2 20 Single-blind 
(assumed); cross-
over
9 9 9 Three-back letter working 
mem paradigm
Nonsignificant
2 Left DLPFC; M1 
(left assumed)
Contralateral 
right orbit
2 20 Single-blind 
(assumed); cross-
over
9 9 9 Three-back letter working 
mem paradigm
Significant (DLPFC 
only)
Fregni et al25 2006 UL 35 1 Left M1 Right 
supraorbital
1 20 Double-blind; 
cross-over
2.4 HY 9 9 9 MEP; UPDRS; sRT; PPT Significant
35 1 Right supraorbital Left M1 1 20 Double-blind; 
cross-over
8 8 8 MEP; UPDRS; sRT; PPT Nonsignificant
35 1 Left DLPFC Right 
supraorbital
1 20 Double-blind; 
cross-over
9 9 9 UPDRS; sRT; PPT Significant
Benninger 
et al26
2010 Gait and 
UL
Reaction 
time
Depression 97.5 (anode); 
25 (cathode)
2 10 cm anterior to 
Cz × 4 sessions; 
prefrontal 
cortices 
(forehead above 
eyebrows) × 4 
sessions
Mastoids 8 (2/3 pw) 20 Double-blind 2.4±0.2 25 13 12 10 m walk; UL 
bradykinesia; UPDRS; sRT; 
BDI; health survey; SelfAx 
of mobility
Nonsignificant
Pereira 
et al76
2013 Verbal 
fluency
35 2 Left DLPFC or 
left TPC
Right 
supraorbital
1 (left 
DLPFC) + 1 
(left TPC)
20 Crossover; 
no blinding (2 
montages tested)
1.6±0.5 
HY
16 32 0 Verbal fluency (fixation, 
repetition, semantic, 
phonemic); fMRI
Significant (DLPFC 
over TPC)
Verheyden 
et al41
2013 Gait and 
posture
Not stated 1 M1 of dominant 
hemisphere
Contralateral 
supraorbital
1 + sham 15 Double-blind; 
cross-over
1–4 HY 20 20 20 Sit to stand; functional 
reach; 180o turn; TUG; 
10 m walk
Nonsignificant
Doruk et al28 2014 UL Exec Mood/
behavior
35 2 Left or right 
DLPFC
Supraorbital 
contralateral 
to anode 
placement
10 (5 pw) 20 Double-blind; 
2 site
18 11 (6+5) 7 TMT A&B; WCST; PCL; 
WM; Stroop; HPVOT; 
CPM; MMSE; BDI; HAS; 
UPDRS III; sRT; 4-CRT; 
PPT; FT; WT; BU; SP
Significant (cog not 
motor)
Kaski et al50 2014 Gait Anode: 40; 
cathode: 40
2 Anterior to Cz Inion 1 15 Double-blind; 
RCT; cross-over
Physical 
therapy during 
stimulation
16 8 8 Gait velocity; TUG Significant
Manenti 
et al54
2014 Gait 35 2 Left then right 
DLPFC for all 
patients
Contralateral 
supraorbital
2 7 Double-blind; 2 
montages tested 
on each patient 
L&R DLPFC
1.3±1.1 10 20 10 TUG Significant (right 
DLPFC)
Valentino 
et al56
2014 Gait Not stated 2 M1 corresponding 
to leg, patient 
started walking 
post freezing
Contralateral 
orbitofrontal
5 20 Double-blind; 
cross-over
2–4 HY 10 10 10 Motor UPDRS; stand-
walk-sit
Significant
Biundo 
et al53
2015 MCI 2 Left DLPFC Right 
supraorbital 
16 (4 pw) 20 Double-blind Computer-
based cog 
training
24 12 12 RBANS Significant
Salimpour 
et al31
2015 UL N/A N/A Experiment 1: No 
stimulation
No 
stimulation
N/A N/A N/A 1–2.5 HY 15 PD + 
15 Healthy
N/A N/A N/A N/A
25 1 Experiment 2: 
Left M1
Right M1 1 25 Not stated 10 10 0 UPDRS (motor assumed); 
bimanual UL task; 
unimanual task; unimanual 
max force
Nonsignificant
25 (assumed) 2 Experiment 3: 
Right M1
Left M1 1 25 Not stated 10 10 0 Motor UPDRS; bimanual 
UL task; unimanual task; 
unimanual max force
Significant
(Continued)
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Authors Year Motor Cognitive Other Electrode 
size (cm2)
Electrode 
intensity 
(mA)
Anode Cathode Sessions Duration 
per session 
(minutes)
Study type Adjunct Disease 
state 
(HY)
Sample Active Sham Outcomes Result
25 (assumed) Not stated Experiment 4: 
Right or left M1
Right or left 
M1
3 
(consecutive 
days)
Not stated Double-blind; 3 
montages tested 
(contra M1 
anode; contra M1 
cathode; sham)
10 10 0 Motor UPDRS; (bimanual 
UL task; unimanual task; 
unimanual max force – all 
assumed)
Significant (cathodal 
montage only)
25 (assumed) 2 Experiment 5: 
Ipsilateral to 
affected side
Contralateral 
to affected 
side
5 (day 1: 
measures; 
days 2–3: 
sham; days 
4–8: stim; 
days 9–10: 
measures)
Not stated Not stated – 
single-blind 
(assumed)
8 8 8 Motor UPDRS; bimanual 
UL task; unimanual task; 
unimanual max force
Significant
Costa-
Ribeiro 
et al49
2017 Gait 35 2 2 cm anterior to 
vertex in sagittal 
midline
Supraorbital 
area of most 
affected side
10 (2/3 pw) 13 Double-blind Gait training 1–3 HY 24 11 11 TUG; UL-MT; MEP; aMT Significant 
Costa-
Ribeiro 
et al49
2016 Gait 35 2 Cz Supraorbital 
contralateral 
to most 
affected side
10 (3 pw) 13 Double-blind; 
RCT
Cued gait 
training
24 11 11 10 m walk; TUG; cadence; 
stride
Nonsignificant
Ferrucci 
et al33 
2016 Dyskinesia 35 2 1–2 cm below 
inion 
Shoulder 5 + sham 20 Double-blind; 
cross-over
2–3 HY 9 9 4 UPDRS III &IV; PDQ-8; 
BDI; VAT; sRT
Significant
35 2 Left and right M1 Right deltoid 5 + sham 20 Double-blind; 
cross-over
2–3 HY 9 9 5 UPDRS III &IV; PDQ-8; 
BDI; VAT; sRT
Significant
Manenti 
et al52
2016 MCI 35 2 DLPFC – 
contralateral to 
most affected side
Ipsilateral 
supraorbital
10 (5 pw) 25 Double blind Physical 
therapy during 
stimulation
2.2/2.3 
HY
20 10 10 PDCRS Significant
Schabrun 
et al30
2016 Gait 35 2 Left M1  Contralateral 
supraorbital
9 (3 pw) 20 Double-blind; 
parallel group 
design
Gait training 2–3 HY 16 8 8 Gait speed, step 
length, cadence, TUG, 
bradykinesia, motor speed
Nonsignificant
Swank et al55 2016 Gait Not stated 2 Left DLPFC Right DLPFC 1 active; 1 
sham
20 Single-blind 
(assumed); cross-
over
2 HY 
(median)
10 10 10 TUG (alone); TUG 
(manual); TUG (cognitive); 
PDQ-39
Nonsignificant
Forogh 
et al82
2017 Fatigue/
daytime 
sleepiness
35 2 (assumed) Left DLPFC Right DLPFC 8 (2 weeks) 20 Double-blind Occupational 
therapy
23 12 11 FSI; ESS Significant (fatigue 
only)
Lattari et al51 2017 Balance and 
gait
35 2 Left DLPFC Right 
supraorbital 
cortex
1 20 Double-blind; 
cross-over
2.35±1.06 17 17 17 Berg; DGI; TUG Significant – all 
measures
Abbreviations: DLPFC, dorsolateral prefrontal cortex; Exec, executive function; M1, primary motor cortex; MCI, mild cognitive impairment; PD, Parkinson’s disease; TPC, 
temporoparietal cortex; UL, upper limb; sRT, simple reaction time; UPDRS, Unified Parkinson’s Disease Rating Scale; MEP, motor-evoked potential; tDCS, transcranial direct 
current stimulation; fMRI, functional MRI. N/A, not available; HY, Hoehn & Yahr; RCT, randomized controlled trial; PPT, Purdue Pegboard Test; WCST, Wisconsin Card 
Sorting Test; CPM, Colored Progressive Matrices; MMSE Mini mental state examination; HPVOT, Hooper Visual Organization Test; HAS, Hamilton Anxiety Scale; 4-CRT, 
4-choice reaction time; FT, Finger Tapping; WT, walking time; BU, buttoning up; SP supination-pronation; RBANS, Repeatable battery assessment of neuropsychological 
status; aMT, active motor threshold; PDQ8 Parkinson’s disease quality of life questionnaire; VAT, visual attention task; PDCRS, parkinson’s disease cognitive rating scale; 
FSI, fatigue severity index; ESS, Epworth Sleepiness Scale; DGI, dynamic gait index; Berg, Berg Balance Scale; UL-MT, upper limb motor task; stim, stimulation; SelfAx, self-
assessment; BDI, Beck Depression Index; TUG, timed up and go; cog, cognition; L&R, left and right; PCL, probabilistic classification learning; TMT A&B, trial making tests 
A&B; WM, working memory; pw, per week; TPC, temporoparietal cortex; Cz, central electrode in 10–20 electroencephalogram placement.
Table 1 (Continued)
the time taken to complete a variety of motor sequences 10 
times as a measure of bradykinesia. They found no benefit 
of tDCS above and beyond the gait training. 
Salimpour et al31 conducted a study to evaluate the 
subjective cost of producing force with either upper limb in 
patients with PD. They applied simultaneous tDCS to both 
the motor cortices to alter the degree of “noise” associated 
with a particular limb movement. As a part of this study, they 
performed a double-blind assessment in 10 PD patients and 
performed a clinical examination on 3 separate days. On each 
day, subjects received anodal, cathodal, or sham stimulation 
over the motor cortex contralateral to the affected side. The 
order of stimulation was randomized and blinded to the 
clinical raters. They observed a significant improvement in 
UPDRS following cathodal stimulation compared to both 
anodal stimulation and sham. UPDRS showed only a trend 
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Authors Year Motor Cognitive Other Electrode 
size (cm2)
Electrode 
intensity 
(mA)
Anode Cathode Sessions Duration 
per session 
(minutes)
Study type Adjunct Disease 
state 
(HY)
Sample Active Sham Outcomes Result
25 (assumed) Not stated Experiment 4: 
Right or left M1
Right or left 
M1
3 
(consecutive 
days)
Not stated Double-blind; 3 
montages tested 
(contra M1 
anode; contra M1 
cathode; sham)
10 10 0 Motor UPDRS; (bimanual 
UL task; unimanual task; 
unimanual max force – all 
assumed)
Significant (cathodal 
montage only)
25 (assumed) 2 Experiment 5: 
Ipsilateral to 
affected side
Contralateral 
to affected 
side
5 (day 1: 
measures; 
days 2–3: 
sham; days 
4–8: stim; 
days 9–10: 
measures)
Not stated Not stated – 
single-blind 
(assumed)
8 8 8 Motor UPDRS; bimanual 
UL task; unimanual task; 
unimanual max force
Significant
Costa-
Ribeiro 
et al49
2017 Gait 35 2 2 cm anterior to 
vertex in sagittal 
midline
Supraorbital 
area of most 
affected side
10 (2/3 pw) 13 Double-blind Gait training 1–3 HY 24 11 11 TUG; UL-MT; MEP; aMT Significant 
Costa-
Ribeiro 
et al49
2016 Gait 35 2 Cz Supraorbital 
contralateral 
to most 
affected side
10 (3 pw) 13 Double-blind; 
RCT
Cued gait 
training
24 11 11 10 m walk; TUG; cadence; 
stride
Nonsignificant
Ferrucci 
et al33 
2016 Dyskinesia 35 2 1–2 cm below 
inion 
Shoulder 5 + sham 20 Double-blind; 
cross-over
2–3 HY 9 9 4 UPDRS III &IV; PDQ-8; 
BDI; VAT; sRT
Significant
35 2 Left and right M1 Right deltoid 5 + sham 20 Double-blind; 
cross-over
2–3 HY 9 9 5 UPDRS III &IV; PDQ-8; 
BDI; VAT; sRT
Significant
Manenti 
et al52
2016 MCI 35 2 DLPFC – 
contralateral to 
most affected side
Ipsilateral 
supraorbital
10 (5 pw) 25 Double blind Physical 
therapy during 
stimulation
2.2/2.3 
HY
20 10 10 PDCRS Significant
Schabrun 
et al30
2016 Gait 35 2 Left M1  Contralateral 
supraorbital
9 (3 pw) 20 Double-blind; 
parallel group 
design
Gait training 2–3 HY 16 8 8 Gait speed, step 
length, cadence, TUG, 
bradykinesia, motor speed
Nonsignificant
Swank et al55 2016 Gait Not stated 2 Left DLPFC Right DLPFC 1 active; 1 
sham
20 Single-blind 
(assumed); cross-
over
2 HY 
(median)
10 10 10 TUG (alone); TUG 
(manual); TUG (cognitive); 
PDQ-39
Nonsignificant
Forogh 
et al82
2017 Fatigue/
daytime 
sleepiness
35 2 (assumed) Left DLPFC Right DLPFC 8 (2 weeks) 20 Double-blind Occupational 
therapy
23 12 11 FSI; ESS Significant (fatigue 
only)
Lattari et al51 2017 Balance and 
gait
35 2 Left DLPFC Right 
supraorbital 
cortex
1 20 Double-blind; 
cross-over
2.35±1.06 17 17 17 Berg; DGI; TUG Significant – all 
measures
Abbreviations: DLPFC, dorsolateral prefrontal cortex; Exec, executive function; M1, primary motor cortex; MCI, mild cognitive impairment; PD, Parkinson’s disease; TPC, 
temporoparietal cortex; UL, upper limb; sRT, simple reaction time; UPDRS, Unified Parkinson’s Disease Rating Scale; MEP, motor-evoked potential; tDCS, transcranial direct 
current stimulation; fMRI, functional MRI. N/A, not available; HY, Hoehn & Yahr; RCT, randomized controlled trial; PPT, Purdue Pegboard Test; WCST, Wisconsin Card 
Sorting Test; CPM, Colored Progressive Matrices; MMSE Mini mental state examination; HPVOT, Hooper Visual Organization Test; HAS, Hamilton Anxiety Scale; 4-CRT, 
4-choice reaction time; FT, Finger Tapping; WT, walking time; BU, buttoning up; SP supination-pronation; RBANS, Repeatable battery assessment of neuropsychological 
status; aMT, active motor threshold; PDQ8 Parkinson’s disease quality of life questionnaire; VAT, visual attention task; PDCRS, parkinson’s disease cognitive rating scale; 
FSI, fatigue severity index; ESS, Epworth Sleepiness Scale; DGI, dynamic gait index; Berg, Berg Balance Scale; UL-MT, upper limb motor task; stim, stimulation; SelfAx, self-
assessment; BDI, Beck Depression Index; TUG, timed up and go; cog, cognition; L&R, left and right; PCL, probabilistic classification learning; TMT A&B, trial making tests 
A&B; WM, working memory; pw, per week; TPC, temporoparietal cortex; Cz, central electrode in 10–20 electroencephalogram placement.
toward significant change after anodal stimulation (p=0.06). 
These results are contrary to those of Benninger et al26 who 
also used M1 stimulation, although they did not specifi-
cally stimulate contralateral to the affected side. Moreover, 
Salimpour et al31 did not test patients in the “off ” medication 
condition, which was associated with the greatest clinical 
improvement in motor function in the Benninger study.
tDCS for tremor in PD
There have been very few studies of tDCS focusing specifi-
cally on the treatment of tremor in PD. In their randomized, 
double-blind, sham-controlled study design, Benninger et al26 
found no improvement in self-reported tremor scores using 
anodal tDCS over the premotor and motor or prefrontal 
cortices. In addition, although the study was not powered to 
perform comparative analysis of UPDRS subscores, Fregni 
et al25 reported a 10% improvement in tremor scores on the 
UPDRS with anodal tDCS over M1.
tDCS for dyskinesia in PD
The development of Levodopa-induced dyskinesia may have 
a significant negative impact on quality of life among some 
PD patients and is thought to arise due to aberrant plasticity 
within the denervated striatum.32 Recently, Ferrucci et al33 
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investigated the effect of tDCS on dyskinesia, motor, and 
cognitive domains. In this sham-controlled study, nine 
participants received two active stimulation protocols in a 
random order. Motor cortex stimulation consisted of anodal 
stimulation to left and right M1 (with a third electrode – the 
cathode – placed over the deltoid). Cerebellar stimulation 
utilized a previously validated protocol, with the anode 
placed 1–2 cm below the inion and the reference electrode 
positioned over the shoulder. Active stimulation was delivered 
over 5 consecutive days for 20 minutes at 2 mA intensity. 
Compared to baseline, dyskinesias (measured using the 
UPDRS IV – Dyskinesia) on the final day of stimulation 
(day 5) showed a significant improvement from baseline in 
both the active experiments and compared to sham stimula-
tion. Interestingly, the authors saw no change in other motor 
or cognitive domains.
tDCS for gait in PD
Postural instability and gait dysfunction are cardinal motor 
features of PD, often leading to significant reduction in qual-
ity of life34 and predispose sufferers to falls, with associated 
increased morbidity and mortality.35,36 Parkinsonian gait is 
characterized by reduced step and stride length, shuffling of 
the feet, difficulty turning, and freezing of gait (FOG). An 
appreciation of the neuronal mechanisms underpinning gait 
and postural disturbance in PD can help guide therapeutic 
treatments using tDCS in relation to the most appropri-
ate electrode montages to use. In healthy individuals, the 
supplementary motor area (SMA) displays high activity 
during internally driven movements, while premotor areas 
are relatively more involved when a movement is externally 
cued.37 However, in patients with PD, the activity within the 
SMA is reduced, which may be related to the difficulty in 
preparing instructions to trigger a movement.38,39  
Premotor and primary motor regions appear to be relevant 
therapeutic targets for patients with PD and gait disturbance.40 
On the basis of this, Benninger et al26 studied the change in 
the timed test of gait in the “on” and “off ” state 24 hours 
after the tDCS intervention period compared with baseline. 
Assessments were taken over a 3-month period. Twenty-five 
PD patients were investigated, 13 receiving tDCS and 12 sham 
stimulation. tDCS led to a significant decrease in walking time 
with the removal of one outlier from the sham stimulation 
group (−22.6% vs 3.6%; p=0.002). No differences were seen 
when “on” (−17.4% vs −12.7%; p=0.44) or beyond the imme-
diate post-intervention period at 1 or at 3 months thereafter.
Verheyden et al41 conducted a double-blind, experimental 
crossover study with 20 PD patients undergoing either active 
(1 mA for 15 minutes) or sham tDCS. The anode was placed 
over M1 of the dominant hemisphere and the cathode over 
the contralateral supraorbital region. Each patient acted as 
their own control and was assessed in the “on” medication 
state. Patients performed a battery of clinical measures 
prior to tDCS, namely timed sit-to-stand, functional reach, 
standing-start 180° turning, Timed Up and Go (TUG) test, 
and 10 m walk test. Either active or sham tDCS was then 
delivered while the participants repeated the measures. 
Finally, the outcome measures were collected again fol-
lowing the stimulation. The authors observed no significant 
improvement with active tDCS across any outcome. In fact, 
there was a decline in the time taken to complete the 10 m 
walk following active tDCS. Given that PD may show hemi-
spheric lateralization, one explanation offered for the negative 
result was that application over a single hemisphere may in 
fact alter inter-hemispheric balance and lead to relatively 
impaired functional outcomes, that is, increasing cortical 
excitability of one hemisphere may lead to relative decrease 
in cortical excitability of the other hemisphere through inter-
hemispheric inhibition.42  
Combining tDCS with cueing and/
or physical training
It was hypothesized that the combination of tDCS with physi-
cal therapies could optimize the neuroplastic changes induced 
by motor practices and lead to greater and longer-lasting 
clinical gains in neurological rehabilitation. Cueing is an 
established technique that utilizes somatosensory, auditory, 
and visual information to provide timing or spatial stimuli 
to facilitate the initiation and continuation of motor activ-
ity. Several clinical trials indicate cueing therapy-induced 
improvements in walking speed, step length, and frequency 
in PD.43–46 From a neuroanatomical perspective, enhanced 
activation of the premotor cortex seems to be relevant for 
the improvement of motor performance induced by cueing 
therapy.47
Thus, Costa-Ribeiro et al29 investigated the effects of 
tDCS combined with cued gait training (CGT) on functional 
mobility in patients with PD. They conducted a pilot double-
blind controlled, randomized clinical trial with patients 
assigned either to anodal tDCS with CGT (n=12, one lost 
to follow-up) or to sham tDCS with CGT (n=12, one lost to 
follow-up). Functional mobility was assessed by 10 m walk 
test, cadence, stride length, and TUG. All the outcomes 
improved with CGT except stride length and TUG test perfor-
mance. However, gait training effects associated with visual 
cues were not influenced by tDCS on any of these outcomes. 
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Interestingly, TUG and gait velocity showed improvement 
gains to be maintained at 1 month only in the active tDCS 
group. These results suggest that tDCS may indeed prolong 
the effectiveness of cued therapies in PD patients, but in itself 
it does not increase the effect size achieved with CGT alone. 
Different stimulation areas between studies are a potential 
factor to explain the differences observed in the results, given 
that stimulation over premotor and primary motor areas seem 
to be more effective in improving gait in PD compared to 
SMA stimulation. Indeed, a separate study using an externally 
guided task also failed to show the after-effects of repetitive 
TMS over the SMA on performance of a tapping task.48
In a follow-up randomized, double-blind, controlled 
study,49 the same authors investigated the dopamine-
dependent effect of combining tDCS with visual CGT. They 
evaluated the TUG as a measure of functional mobility in 22 
patients with PD. The experimental group (n=11) received 
active anodal tDCS over the SMA and the control group 
(n=11) sham tDCS, in both “on” and “off ” medication states. 
Both the groups received visual CGT following the tDCS. 
Functional mobility improved in either “on” or “off ” medica-
tion conditions compared with baseline, irrespective of tDCS. 
However, for both the medication conditions, these improve-
ments were maintained at 1 month only in the experimental 
group. These findings further support that tDCS can prolong 
the positive effect induced by CGT on functional mobility but 
that such effects are unrelated to dopaminergic medication.
One possible explanation for the lack of efficacy of tDCS 
upon gait observed in these studies is that given the bilateral 
representation of cortical gait regions, one might expect 
improvements in gait to require simultaneous modulation 
of cortical activity bilaterally. Although cortical leg stimula-
tion using non-invasive techniques is more challenging than 
upper limb cortical stimulation given its deeper anatomical 
location, and more vertical orientation than the hand motor 
cortex, experimental evidence has shown that a single anode 
electrode placed over right and left M1 and premotor cortices 
can alter cortical excitability in both the legs simultaneously. 
On the basis of this, Kaski et al50 combined a midline anodal 
tDCS montage (15 minutes of 2 mA current over midline 
primary motor and premotor cortex) with physical train-
ing in a double-blind, cross-over design. One group (n=8) 
underwent gait and balance training during tDCS. Patients 
received the opposite stimulation with physical training 1 
week later. The second group (n=8) received stimulation but 
no training, and also repeated a tDCS session 1 week later. 
Physical training consisted of a systematic set of exercises 
relating to gait and balance repeated over a single 30-minute 
session. Outcomes included gait velocity, stride length, timed 
6-minute walk test, TUG, and performance on the pull test. 
The combination of tDCS with physical training increased 
gait velocity (mean =29.5%, SD =13; p<0.01) and improved 
balance above and beyond the effects of tDCS alone. Greater 
tDCS-related improvements were observed in patients with 
higher UPDRS scores (ie, more severe disease). 
Schabrun et al did not find any benefit of tDCS above and 
beyond physical training.30 They investigated the feasibility 
and safety of combining anodal tDCS with a dual task gait 
training intervention in 16 patients with PD. They performed 
a pilot, randomized, double-blind, sham-controlled paral-
lel group trial with 12-week follow-up. Patients received 
nine dual task gait training sessions over 3 weeks and were 
randomized to receive active or sham tDCS over the first 20 
minutes of each session. Outcomes included gait speed, step 
length, cadence, and TUG, all during a concurrent cognitive 
task (eg, counting). Gait speed, step length, and cadence 
improved in both the groups, under all dual task conditions. 
This effect was maintained at follow-up. There was no dif-
ference between the active and sham tDCS groups. 
While most studies of tDCS assessing gait and balance 
in PD have focused on the primary motor and premotor cor-
tex, Lattari et al51 investigated the effects of active (anodal) 
stimulation over the left DLPFC (2 mA for 20 minutes) on 
balance and mobility in 17 patients with PD, on medication. 
They ran a double-blind, randomized, cross-over trial with 
each participant undergoing anodal tDCS and sham tDCS, 
with a minimum washout period of 48 hours. They recorded 
the Berg Balance Scale, Dynamic Gait Index and TUG. 
DLPFC anodal tDCS improved all measures as compared 
to sham stimulation. The authors argue that reduced SMA 
activity in patients with PD leads to enhanced activity in other 
cortical regions, including the DLPFC, thus accounting for 
motor improvements in their study. Alternatively, tDCS may 
have enhanced visuo-spatial processing, or indeed activated 
neighboring lateral prefrontal regions involved in compensat-
ing for reduced SMA activity.
Manenti et al52 also investigated repeated sessions of 
DLPFC tDCS combined with physical training upon motor 
and cognitive performance. The authors administered 2 mA 
anodal tDCS to the DLPFC contralateral to the patients’ most 
affected side, together with physical therapy for 25 minutes 
a day, 5 days a week, for 2 weeks. They found no significant 
benefit of tDCS compared to sham stimulation in tests of 
gait and stance, although both the groups improved over 
time, likely as a result of both learning effects and physi-
cal therapy; there was however a reported  improvement in 
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cognitive performance. Similar findings on motor function 
(UPDRS part III) were found by Biundo et al53 using a similar 
stimulation and therapy protocol. While this study did not 
focus on motor outcomes, no significant shift in motor scores 
following repeated sessions of stimulation was observed; 
however, a trend for improved performance in specific cogni-
tive domains was reported.
In an earlier study, Manenti et al54 reported improved gait 
performance, as measured by the TUG immediately follow-
ing anodal tDCS of the right DLPFC. They rationalized that 
frontal areas are active during locomotion and that tDCS may 
play a role in the modulation of prefrontal dopamine release 
or work to stimulate frontal regions responsible for executive 
function and hence gait. The study involved 10 subjects who 
were administered a modest dose of 2 mA anodal tDCS for 
7 minutes to the left and right DLPFC (on different days) 
and who also received sham stimulation. TUG scores were 
recorded at baseline and following stimulation. Interestingly, 
eight of the subjects were reported to have left side of the 
body as more affected by PD.  
Swank et al55 stimulated the left DLPFC with anodal tDCS 
and compared this to sham stimulation, measuring subject 
performance completing the TUG under three different condi-
tions: 1) TUG alone; 2) TUG while holding a cup of water; 
3) TUG while counting backwards. Active stimulation was 
delivered for 20 minutes at 2 mA to 10 subjects. The authors 
did not report whether any participants exhibited lateralized 
symptoms or presented with a more affected side of the body. 
Interestingly, the active stimulation protocol appeared to have 
no meaningful effect on TUG alone, however did influence 
the performance on TUG while holding a cup of water, and 
most considerably on the TUG while counting backwards. 
This is in keeping with the role of the DLPFC in cognition. 
FOG is considered a discreet clinical entity but may also 
be a feature of PD that represents a disabling motor com-
plication. Valentino et al56 were the first to investigate the 
efficacy of tDCS of the primary motor cortex of PD patients 
with FOG. In this double-blind, sham-controlled, cross-over 
study, 10 PD patients with FOG in the “on” medication state 
underwent 20 minutes of anodal (2 mA) or sham stimulation 
across 5 consecutive days. Clinical assessments were per-
formed over a month. Active stimulation led to a significant 
improvement in the Stand Walk Sit test and a reduction in the 
frequency and duration of FOG episodes. The authors also 
observed an improvement in the motor (part III) and total 
UPDRS with active compared to sham stimulation. Beneficial 
effects were more evident after the entire 5-day stimulation 
session and persisted until the end of the observation period.
The authors suggest that anodal tDCS may have stimu-
lated the release of dopamine through activation of gluta-
matergic cortico-striatal projections.57,58 Alternatively, or 
additionally, tDCS may have induced an excitatory modula-
tion of the cortico-striato-thalamo-cortical circuits that have 
been shown to be impaired in patients with FOG.59 
tDCS for cognition
Cognitive functions are predominantly executed by the cor-
tex, where dopamine is known to be a key neurotransmitter.60 
It has been suggested that disruption of the dopaminergic 
system, as occurs in PD, may be one mechanism involved 
in cognitive impairment.61 Indeed, cognitive impairment is 
a common feature of PD, and although it tends to occur as a 
later manifestation of the condition, it is an important predic-
tor of quality of life in these patients. The characteristics of 
the cognitive impairment observed in PD patients include 
deficits of executive function, such as planning and working 
memory.62,63 Depression in PD has also been associated with 
changes in dopaminergic transmission across cortical and 
subcortical areas, and aberrant neuronal excitability between 
the right and left DLPFC may underpin some of the psychiat-
ric manifestations in patients with PD.64 Indeed, anodal tDCS 
over the left DLPFC with the cathode over the right supra-
orbital region has been shown to improve working memory 
in healthy subjects,65 as well as improve mood in patients 
with major depression.66,67 In this context, several studies 
have documented the beneficial effects of TMS on cognitive 
symptoms in PD68,69 without worsening motor symptoms.70 
These results support the idea that active stimulation of the 
DLPFC with tDCS could also have beneficial effects on both 
affective and cognitive domains in patients with PD.
Boggio et al71 investigated the differential effects of 
1mA versus 2mA anodal tDCS over the left DLPFC, M1 
or sham on the performance of a working memory task 
in 18 PD patients. A significant improvement in working 
memory accuracy, but not speed, was observed only after 
left DLPFC tDCS at 2mA. The results of this study are in 
line with neuroimaging and rTMS evidence showing that 
the left DLPFC is critical to working memory formation.72-73 
Surprisingly, stimulation at 1mA did not induce significant 
effects upon working memory in these patients. The authors 
hypothesized that tDCS may be less effective in older subjects 
and thus higher currents would be required. In support of this 
hypothesis, lesser effects of non-invasive brain stimulation 
have been observed in the elderly compared to a younger 
population.74 Nevertheless, other studies25 have shown that 
1mA stimulation for 20 minutes is able to induce behavioral 
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effects in PD patients of a similar age to those included in 
the Boggio et al71 study. A further possibility is that a 1 mA 
stimulation would be insufficient to induce a significant 
release of dopamine, a possibility supported by studies in 
healthy subjects.75 
Doruk et al28 conducted a multicenter, sham-controlled, 
double-blind study to assess the immediate and long-term 
effects of 10 consecutive sessions of tDCS. Anodal stimula-
tion was delivered either over the right DLPFC (n=5), left 
DLPFC (n=6), or sham (n=7). Cognitive function, depres-
sive symptoms, and motor functions were evaluated in 18 
PD patients at baseline, at the end of the 2-week stimulation 
sessions, and at 1-month follow-up. Their results were mixed, 
showing an improvement in a test of executive function (trail 
making test B) across all groups (including sham, thus likely 
to represent a learning effect), but improvements were only 
sustained at 1-month follow-up in the active left and right 
DLPFC stimulation groups. Such effects were not seen for a 
variety of other cognitive tasks. While the results suggest the 
existence of a beneficial long-term effect on executive func-
tion in PD patients following active tDCS over the DLPFC, 
the authors found no additional benefit of left versus right 
DLPFC stimulation. The authors also reported improvement 
in depressive symptoms at the end of the 10-session interven-
tion, only for left DLPFC tDCS, although baseline depression 
scores were remarkably low in this study. Benninger et al26 
found no significant improvement in depression scores on 
the Beck Depression Inventory following tDCS to the motor 
and prefrontal cortex, but again baseline values were low.
Pereira et al76 compared the effects induced by frontal 
versus temporoparietal tDCS upon phonemic and semantic 
fluency functional networks in patients with PD. They ran-
domized 16 patients with PD to receive tDCS (2 mA for 20 
minutes) to either the left DLPFC or left temporoparietal 
cortex (TPC) in a counterbalanced order. Immediately follow-
ing stimulation, patients underwent a verbal fluency paradigm 
inside a functional MRI scanner. They assessed differences 
in functional connectivity associated with the two different 
stimulation protocols. In addition, and in light of abnormali-
ties in default-mode networks observed in PD,77,78 the authors 
also evaluated the effects of tDCS on task-related pattern 
networks (a distributed brain system normally deactivated 
during attention-demanding tasks) that have neuroanatomi-
cal overlap with default-mode networks. DLPFC tDCS led 
to greater enhancement of functional connectivity in verbal 
fluency and greater deactivation in task-related networks than 
stimulation over TPC. In addition, DLPFC tDCS increased 
performance on the phonemic fluency task hinting at a 
relationship between neurobiologic and behavioral effects. 
Although the authors argue that tDCS stimulation effects on 
brain activity are limited to 10 minutes79 or 15 minutes,80 their 
washout period of only 2 hours may have been a significant 
confounder. Moreover, the authors did not include a sham 
stimulation protocol which makes it difficult to exclude an 
order effect on performance. 
tDCS with cognitive training
Recently, Manenti et al52 demonstrated stimulation to the 
DLPFC contralateral to the patients’ most symptomatic 
side was effective at improving cognitive performance 
among PD subjects compared to sham. In this repeated 
session  experiment, there was improvement immediately 
following, and persistent at 3 months after, stimulation. An 
overall improvement to motor and depressive symptoms was 
observed in both the groups (active and sham) and attributed 
to physical therapy which was provided as an adjunct to all 
participants. 
Manenti et al52 compared the short- and long-term effects 
of active versus sham tDCS combined with physical therapy 
in PD with mild cognitive impairment. PD patients with mild 
cognitive impairment present subtle cognitive dysfunctions, 
such as memory deficits and difficulties in frontal/executive 
abilities, with preserved activities of daily living.81 This 
condition is associated with a higher risk of developing 
Parkinson’s dementia. The authors administered 2 mA tDCS 
DLPFC together with physical therapy for 25 minutes a day, 
5 days a week, for 2 weeks. They found significant improve-
ments in the PD cognitive rating scale, frontal subcortical 
scores, and verbal fluency task, with a stable effect even at 
3 months. A similar trend toward significance was observed 
for the trail making test B (a test of executive function). As 
expected, there were no improvements in a visual memory 
task (not reliant upon the DLPFC) with tDCS, excluding a 
general, nonspecific effect upon cognitive processing. In 
this repeated session experiment, there was improvement 
immediately following, and persistent at 3 months after, 
stimulation. An overall improvement to motor and depressive 
symptoms was observed in both the groups (active and sham) 
and attributed to physical therapy which was provided as an 
adjunct to all participants. 
Biundo et al53 tested 24 subjects with PD, with 16 stimu-
lation sessions over 4 weeks. The anode was placed over 
the left DLPFC of subjects and current was administered 
for 20 min at 2 mA. Interestingly, the researchers chose to 
stimulate in conjunction with simultaneous computer-based 
cognitive training for 30 minutes. They observed a trend for 
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 improvement in memory skills in the active tDCS group 
immediately after stimulation and at 4 weeks follow-up 
(which diminished over time), while another memory-based 
task showed a delayed benefit only at follow-up, 16 weeks 
after stimulation, but no other significant effects across a 
range of cognitive tasks. The authors argue that their use of 
more stringent criteria to define mild cognitive impairment 
(MCI) status compared to Manenti et al52 may explain the 
lack of more widespread effects on cognition in their study. 
tDCS for fatigue and day-time 
sleepiness
Fatigue and sleep abnormalities are common non-motor 
symptoms of PD. Using two validated questionnaires, 
Forogh et al82 investigated the effects of anodal tDCS applied 
over the left DLPFC on fatigue and daytime sleepiness. 
In a double-blind, sham-controlled design, 23 participants 
received either sham (n=11) or real (n=12) stimulation for 
eight sessions (20 min each) over a 2-week period, with a 
current equivalent to 2 mA. Both real and sham stimulations 
were provided in addition to occupational therapy input. 
At 3 months following stimulation, there was a significant 
improvement in the real stimulation group for fatigue but not 
for daytime sleepiness, with no notable change in the sham 
stimulation group. Despite complex multifactorial causes 
for sleep disturbances and fatigue, the authors hypothesized 
that the positive results observed in this study may relate 
to the established effect of tDCS on mood and depressive 
symptoms.83 
Clinical implications
Of the 19 studies included in this review, 14 showed positive 
effects (in at least one experimental condition) of tDCS in 
PD. Thus, taken together, there seems to be strong evidence 
to support the use of tDCS, either alone or in combination 
with physical and cognitive therapies in patients with PD 
and across a range of motor and non-motor symptoms. 
Why then, has tDCS not yet entered mainstream clinical 
practice? Two critical reasons are the large variability in 
study protocols and the small sample sizes studied. Despite 
significant results across some motor and cognitive domains, 
differences in outcomes between studies are often attributed 
to differences in study protocols (eg, delivering 1 mA versus 
2 mA, or stimulating for 15 minutes versus 20 minutes). The 
presence of multiple pilot studies each using different stimu-
lation protocols hinders progress in designing larger scale 
studies. Small sample sizes means that it is difficult to draw 
any firm conclusions, with almost every study reviewed here 
 concluding that there is insufficient power to establish con-
clusive results. One further limiting factor is the publication 
bias that exists in the scientific community, with a tendency 
to publish mostly positive results. 
Specific scientific data aside, it is well recognized by 
technological industries that “implementing new methods, 
guidelines or tools into routine care is a slow and unpredict-
able process, and the factors that play a role in the change 
process are not yet fully understood.”84 Some of the factors 
relate to the nature of the innovation itself (eg, the complexity 
and compatibility of the technology), the characteristics of 
the adopting organization (eg, attitudes and perceptions), and 
behavior pattern characteristics of the adopting organization 
(eg, the size and structure of available resources). This said, 
tDCS has been around for over 100 years now. Therefore, it 
is time to encourage large-scale, multicenter, randomized, 
double-blind, Phase III studies using standardized protocols 
based on the more robust published pilot data.
Key considerations for a large-scale, 
multicenter clinical trial of tDCS  
in PD
Effects of tDCS on dopamine
In a study of anesthetized rats, a 10 minute exposure to cath-
odal tDCS of the frontal lobe resulted in a 60% increase in 
dopamine in the striatum that was sustained for hours after 
cessation of stimulation. Conversely, anodal stimulation 
decreased dopamine concentrations by 10%.20 In healthy 
individuals, anodal tDCS over M1 brings neurons closer to 
depolarization threshold.85 Consistent with animal data, in 
healthy individuals, the excitatory effects of anodal tDCS 
upon neuronal excitability are blunted by l-dopa.27 This may 
explain why some studies have not observed positive effects 
of anodal tDCS in medicated PD patients,26,41 though this 
would be in contrast to other study outcomes.56 While “off ” 
medication states may be of research interest, medication 
withdrawal may be of lesser practical interest in the clinical 
setting. Nevertheless, pilot data suggest that applying tDCS 
during medication troughs may increase the potentiation of 
tDCS effects. 
Online versus offline, with or without 
training? 
The available data suggest that greater effects of tDCS upon 
motor and cognitive function are achieved through online 
tDCS application – that is, delivering tDCS during the con-
current performance of a motor/cognitive task. In addition, 
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the application of online tDCS seems to be enhanced by 
concurrent cognitive/motor training. Future interventions 
need to compare standard (not individualized) and tailored 
(individualized) cognitive training and examine whether 
combining cognitive training with brain stimulation further 
improves cognition in PD. 
Lateralization effects
A clinical feature of PD is the asymmetric onset of motor 
symptoms, corresponding to contralateral neuronal nigro-
striatal degeneration. Indeed, the side of onset may have 
prognostic implications.86 Moreover, cognitive decline in PD 
has been associated with left-sided onset of motor features,87 
hinting at an association between laterality of symptom onset 
and disease progression and severity. Further work is required 
to better characterize the role of lateralization in PD and 
possible associated effects of handedness upon disease onset 
and progression. As such, future studies of tDCS in PD may 
need to consider the effect of lateralization upon symptom 
type and disease progression and severity.
Stimulation duration, current density and 
electrode montages
At present, studies that have focused on the effect of tDCS 
on PD lack the sample sizes and statistical power to be inter-
preted as clinically meaningful to the general population of 
patients, and in addition, many studies have produced results 
at variance. The incongruence of many study outcomes can 
be explained by the vagaries and heterogeneity in study 
design, including electrode montage, stimulation dose, 
and differences in subject populations. In addition, these 
differences make combining the results of smaller studies 
more difficult, limiting the capacity for pooled estimate of 
their effect.
As studies continue to be published, there should be 
an increased focus on the existing consensus for tDCS 
research,88–90 and more specific parameters agreed for PD 
research. Consistent with this, all studies should provide clear 
methodology which details the specifics of the stimulation 
protocol and leaves no ambiguity or need for assumptions 
regarding testing conditions. We recommend that future stud-
ies provide, in addition to conventional scientific rigor (eg, 
randomization concealment, well defined outcomes, mini-
mized bias), a detailed description of methods, including all 
parameters of stimulation, to enable experimental replication 
and allow for future modeling. There should be an increased 
focus on well-defined, robust protocols  exploring session 
duration, repeated measures, and therapy as an adjunct to 
tDCS. As some studies have demonstrated an interplay 
between tDCS and on/off states and more generally with 
PD pharmacological treatments, there is a need to define and 
quantify these clearly in parallel to the stimulation protocol, 
so that their interaction can be better understood.
Disease severity
Studies should also compare interventions between partici-
pant groups with varying severity of cognitive impairment, 
to provide insight into which stages of disease progression 
are most likely to benefit from cognitive training and brain 
stimulation.
A word of caution, however: there is a growing do-it-your-
self tDCS community across the world,91 with a concerning 
expansion in uncontrolled use of tDCS outside clinical and 
academic settings. Trading companies contribute to a mis-
guided development, promoting tDCS outside medical remits 
and instead for the purpose of self-neurological enhancement, 
to improve memory, attention, learning, decision-making, 
problem-solving, sleep, physical endurance, or gaming 
performance.92 Therefore, there is a real need to consider 
tDCS only in light of rigorous clinical studies that have been 
published in reputable peer-reviewed journals.
Conclusion
PD is a progressive neurodegenerative disorder characterized 
by motor and non-motor complications that arise from both 
the underlying disease process and in relation to medication 
use. While invasive treatments such as DBS have revolution-
ized the management of PD, such treatments carry significant 
anesthetic and surgical risks. Therefore, there is a growing 
need to translate the positive findings of non-invasive brain 
stimulation (particularly tDCS) studies upon motor and non-
motor PD symptoms into mainstream clinical practice. To do 
so, large-scale, multicenter, randomized, double-blind, Phase 
III studies using standardized protocols based on the more 
robust published pilot data should be encouraged, in prefer-
ence to small-scale proof-of-principle pilot studies. Future 
tDCS studies in PD should therefore carefully consider the 
role of dopamine, disease severity, adjunctive physical or 
cognitive therapies, lateralization effects of tDCS, stimulation 
duration, current density, and electrode montages based on 
currently available evidence.
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